Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)
Open Access
- 2 January 2014
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 123 (1) , 78-85
Abstract
Key Points: First prospective US cooperative trial group in preneoplastic gammopathies. Prospective demonstration that genomic features of preneoplastic cells predict disease risk.Keywords
This publication has 43 references indexed in Scilit:
- Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myelomaLeukemia, 2013
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple myelomaLeukemia, 2012
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewLeukemia, 2009
- Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseBlood, 2008
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaBlood, 2008
- Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple MyelomaNew England Journal of Medicine, 2007
- Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathyJournal of Experimental Medicine, 2007
- The molecular classification of multiple myelomaBlood, 2006
- Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantationBlood, 2006
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003